Published in Prog Neurobiol on August 21, 2009
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist (2011) 1.22
Beyond faithful conduction: short-term dynamics, neuromodulation, and long-term regulation of spike propagation in the axon. Prog Neurobiol (2011) 1.16
Dopamine modulates Ih in a motor axon. J Neurosci (2010) 0.89
Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes. Diabetes (2012) 0.87
In vivo loss of slow potassium channel activity in individuals with benign familial neonatal epilepsy in remission. Brain (2012) 0.84
Potassium and the excitability properties of normal human motor axons in vivo. PLoS One (2014) 0.83
Dopamine modulation of Ih improves temporal fidelity of spike propagation in an unmyelinated axon. J Neurosci (2012) 0.82
Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD. Clin J Am Soc Nephrol (2017) 0.82
Nerve excitability assessment in chemotherapy-induced neurotoxicity. J Vis Exp (2012) 0.80
Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability. J Physiol (2012) 0.79
Excitability and the safety margin in human axons during hyperthermia. J Physiol (2013) 0.79
Reduction in neural performance following recovery from anoxic stress is mimicked by AMPK pathway activation. PLoS One (2014) 0.79
Effects of axonal ion channel dysfunction on quality of life in type 2 diabetes. Diabetes Care (2013) 0.79
Axonal Excitability in Amyotrophic Lateral Sclerosis : Axonal Excitability in ALS. Neurotherapeutics (2016) 0.79
Neurodegeneration in Autoimmune Optic Neuritis Is Associated with Altered APP Cleavage in Neurons and Up-Regulation of p53. PLoS One (2015) 0.78
IH activity is increased in populations of slow versus fast motor axons of the rat. Front Hum Neurosci (2014) 0.78
Sustained maximal voluntary contraction produces independent changes in human motor axons and the muscle they innervate. PLoS One (2014) 0.77
Short-term peripheral nerve stimulation ameliorates axonal dysfunction after spinal cord injury. J Neurophysiol (2015) 0.77
Strength-duration time constant in peripheral nerve: no abnormality in multiple sclerosis. Mult Scler Int (2012) 0.77
The development and modelling of devices and paradigms for transcranial magnetic stimulation. Int Rev Psychiatry (2017) 0.75
Impaired Axonal Na(+) Current by Hindlimb Unloading: Implication for Disuse Neuromuscular Atrophy. Front Physiol (2016) 0.75
Axonal Dysfunction Precedes Motor Neuronal Death in Amyotrophic Lateral Sclerosis. PLoS One (2016) 0.75
Abnormal electrocardiogram in a patient with amyotrophic lateral sclerosis mimicking myocardial ischaemia. World J Clin Cases (2014) 0.75
Emergence of a predictive clinical biomarker for diabetic neuropathy. Diabetes (2012) 0.75
The Relationship between Dyslipidemia and Acute Axonal Function in Type 2 Diabetes Mellitus In Vivo. PLoS One (2016) 0.75
Accommodation to hyperpolarization of human axons assessed in the frequency domain. J Neurophysiol (2016) 0.75
Excitability properties of motor axons in adults with cerebral palsy. Front Hum Neurosci (2015) 0.75
Peripheral nerve axonal excitability studies: expanding the neurophysiologist's armamentarium. Cerebellum Ataxias (2015) 0.75
Burning pain: axonal dysfunction in erythromelalgia. Pain (2017) 0.75
Rearrangement of potassium ions and Kv1.1/Kv1.2 potassium channels in regenerating axons following end-to-end neurorrhaphy: ionic images from TOF-SIMS. Histochem Cell Biol (2017) 0.75
Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol (2013) 2.52
Guillain-Barré syndrome: an update. J Clin Neurosci (2009) 2.46
Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol (2009) 2.20
Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 2.08
Botulinum toxin modulates cortical maladaptation in post-stroke spasticity. Muscle Nerve (2013) 2.00
Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain (2008) 1.94
Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann Neurol (2005) 1.86
Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2011) 1.75
Segmental facial anhidrosis and tonic pupils with preserved deep tendon reflexes: a novel autonomic neuropathy. J Neuroophthalmol (2005) 1.63
Heterogeneity of phasic cholinergic signaling in neocortical neurons. J Neurophysiol (2006) 1.60
Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol (2011) 1.59
Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol (2011) 1.55
Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol (2008) 1.54
Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.52
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain (2009) 1.50
Changes in human sensory axonal excitability induced by an ischaemic insult. Clin Neurophysiol (2008) 1.49
Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.49
Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain (2006) 1.47
Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clin Neurophysiol (2010) 1.47
FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry (2009) 1.44
Riluzole: a glimmer of hope in the treatment of motor neurone disease. Med J Aust (2005) 1.42
Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clin Neurophysiol (2010) 1.41
Scurvy and stroke - is there an association? Med J Aust (2010) 1.40
Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve (2005) 1.37
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol (2009) 1.37
Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin (2014) 1.36
Neurotoxic marine poisoning. Lancet Neurol (2005) 1.33
Motor neuron dysfunction in frontotemporal dementia. Brain (2011) 1.31
Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve (2007) 1.30
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist (2011) 1.22
Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol (2006) 1.22
Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr Mol Med (2009) 1.19
Motoneuron excitability and the F wave. Muscle Nerve (2003) 1.18
Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2012) 1.18
Fatigue in multiple sclerosis: mechanisms and management. Clin Neurophysiol (2010) 1.18
Altered nerve excitability properties in established diabetic neuropathy. Brain (2005) 1.17
Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve (2006) 1.17
Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One (2012) 1.15
Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry (2012) 1.14
Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain (2008) 1.10
FOSMN syndrome: novel insight into disease pathophysiology. Neurology (2012) 1.10
How common are behavioural changes in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2010) 1.09
Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum. Amyotroph Lateral Scler (2012) 1.08
Differences in activity-dependent hyperpolarization in human sensory and motor axons. J Physiol (2004) 1.06
Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 1.05
Changes in human sensory axonal excitability induced by focal nerve compression. J Physiol (2010) 1.04
Altered motor nerve excitability in end-stage kidney disease. Brain (2005) 1.02
Nerve function and dysfunction in acute intermittent porphyria. Brain (2008) 1.00
Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res (2006) 1.00
Engaging in patient decision-making in multidisciplinary care for amyotrophic lateral sclerosis: the views of health professionals. Patient Prefer Adherence (2012) 1.00
Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 0.98
Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer (2012) 0.98
Differences in membrane properties of axonal and demyelinating Guillain-Barré syndromes. Ann Neurol (2002) 0.96
INSPIRATIonAL--INSPIRAtory muscle training in amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2009) 0.96
Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry (2009) 0.95
Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain (2010) 0.95
Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol (2014) 0.94
Threshold behaviour of human axons explored using subthreshold perturbations to membrane potential. J Physiol (2008) 0.94
Axonal changes in spinal cord injured patients distal to the site of injury. Brain (2007) 0.94
Neurological complications of chronic kidney disease. Nat Rev Neurol (2009) 0.93
Has potassium been prematurely discarded as a contributing factor to the development of uraemic neuropathy? Nephrol Dial Transplant (2004) 0.93
Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain (2013) 0.92
Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One (2011) 0.92
Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry (2013) 0.92
Assessment of disease progression in motor neuron disease. Lancet Neurol (2005) 0.91
Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. Amyotroph Lateral Scler (2011) 0.91
Assessing the accuracy of a combination of clinical tests for identifying carpal tunnel syndrome. J Clin Neurosci (2009) 0.90
Congenital myasthenic syndromes. J Clin Neurosci (2008) 0.90
Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes. Neurology (2013) 0.90
Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr (2012) 0.89
The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol (2010) 0.89
Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst (2008) 0.88
Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle Nerve (2010) 0.88
Puffer fish poisoning: a potentially life-threatening condition. Med J Aust (2002) 0.88
Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002). J Clin Neurosci (2006) 0.87
Predicting a positive response to intravenous immunoglobulin in isolated lower motor neuron syndromes. PLoS One (2011) 0.87
The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Res (2009) 0.87
Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes. Diabetes (2012) 0.87
Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Exp Neurol (2009) 0.86
Excitability changes in human peripheral nerve axons in a paradigm mimicking paired-pulse transcranial magnetic stimulation. J Physiol (2002) 0.86
The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol (2013) 0.86